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Abstract
Aims: A loss in brain acetylcholine and cholinergic markers, subchronic inflammation, and impaired mito-
chondrial function, which lead to low-energy production and high oxidative stress, are common pathological
factors in several neurodegenerative diseases (NDDs). Glial cells are important for brain homeostasis, and
microglia controls the central immune response, where a7 acetylcholine nicotinic receptors (nAChR) seem to
play a pivotal role; however, little is known about the effects of this receptor in metabolism. Therefore, the aim
of this study was to evaluate if glial mitochondrial energetics could be regulated through a7 nAChR.
Results: Primary glial cultures treated with the a7 nicotinic agonist PNU282987 increased their mitochondrial mass
and their mitochondrial oxygen consumption without increasing oxidative stress; these changes were abolished
when nuclear erythroid 2-related factor 2 (Nrf2) was absent, heme oxygenase-1 (HO-1) was inhibited, or peroxi-
some proliferator-activated receptor gamma coactivator 1a (PGC-1a) was silenced. More specifically, microglia of
animals treated intraperitoneally with the a7 nAChR agonist PNU282987 (10mg/kg) showed a significant increase
in mitochondrial mass. Interestingly, LysMcre-Hmox1D/D and PGC-1a-/- animals showed lower microglial mito-
chondrial levels and treatment with PNU282987 did not produce effects on mitochondrial levels.
Innovation: Increases in microglial mitochondrial mass and metabolism can be achieved via a7 nAChR by a
mechanism that implicates Nrf2, HO-1, and PGC-1a. This signaling pathway could open a new strategy for the
treatment of NDDs, such as Alzheimer’s, characterized by a reduction of cholinergic markers.
Conclusion: a7 nAChR signaling increases glial mitochondrial mass, both in vitro and in vivo, via HO-1 and
PCG-1a. These effects could be of potential benefit in the context of NDDs. Antioxid. Redox Signal. 27, 93–105.
Keywords: mitochondrial biogenesis, alpha-7 nicotinic receptors, heme-oxygenase-1, PGC-1alpha, microglia,
PNU282987
Introduction
Aging and neurodegeneration share common factorssuch as low-grade chronic inflammation and im-
paired mitochondrial function, which lead to low energy
production and high oxidative stress (8). Furthermore, in-
herited mitochondrial defects have also been related to neu-
rodegeneration. Indeed, dysfunctional mitochondria are the
main source of reactive oxygen species (ROS) production.
Mitochondria are the main producers of adenosine tri-
phosphate (ATP), and therefore, a reduction in their number
or functionality is translated into a reduction in brain ener-
getic metabolism, which alters brain function. Beyond energy
production, mitochondria serve for multiple functions, such
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as controlling the levels of metabolites, amino acids, or co-
factors of regulating enzymes, synthesis of heme and Fe-S
clusters, and calcium homeostasis (25). Therefore, strategies
based on increasing mitochondrial number could be of po-
tential interest to provide neuroprotection.
Mitochondria have a limited half-life and cells can respond to
different situations by controlling theirmitochondrial content by
different pathways, among others through mitochondrial bio-
genesis. Mitochondrial biogenesis is a highly controlled and
coordinatedmechanism that implicates the transcription of both,
nuclear and mitochondrial genes. There are a large number of
physiological and pathological situations that demand an in-
crease in mitochondrial number, such as nutrient deficits, tem-
perature changes, exercise, hormonesor growth factors (40), and
inflammatory resolution (34). Different transcription factors are
implicated in mitochondrial biogenesis, such as the nuclear re-
spiratory factors (NRF-1 and NRF-2), members of the nuclear
receptor (NR), the peroxisome proliferator-activated receptors
(PPARs), the estrogen-related receptors (ERRs) (13), or addi-
tional transcription factors, including YY1, MEF2, and c-myc
(41). Regardless of the transcription factor implicated, these
signals converge in the activation of transcriptional coactivator
peroxisome proliferator-activated receptor gamma coactivator-
1a (PGC-1a)which acts as themaster regulator ofmitochondrial
biogenesis.
PGC-1a integrates the activity of a variety of transcription
factors such as NRF1-2, PPARa, and mitochondrial transcrip-
tion factor A (mtTFA), regulating the generation of new mito-
chondria and the cellular energetic status (6, 10, 13). Several
studies have demonstrated that PGC-1a is involved in the acti-
vation of the mitochondrial respiratory chain and fatty acid ox-
idation genes, and also in increasing mitochondrial number and
respiratory capacity (41). PGC-1a also plays a pivotal role in
controlling the cellular antioxidant responses since it controls the
expression of many antioxidant genes such as glutathione per-
oxidase, catalase, or superoxide dismutase-1 (43). In this way,
PGC-1a controls the generation of new mitochondria without
increasing cellular oxidative stress. Moreover, deficiency in
PGC-1a relates to early neurodegeneration (17) and alterations
in this transcription factor have been related to the progression of
different neurodegenerative diseases (NDDs) (4a).
Nicotinic acetylcholine receptors (nAChRs) are a family of
ion-gated channels, which are expressed both in the periphery
and in the central nervous system (CNS). Within the brain, the
a7 nAChR subtype is expressed both in neurons, where it
controls neurotransmission or neurite outgrowth, and in mi-
croglia, where it is known to control the cholinergic anti-
inflammatory pathway. Furthermore, its activation has been
reported to exert neuroprotection against a variety of patho-
logical situations (12, 36); the intracellular signaling pathway
to afford neuroprotection includes activation of the transcrip-
tion factor nuclear erythroid 2-related factor 2 (Nrf2) (12, 22,
30), considered as the master regulator of redox homeostasis.
When Nrf2 is activated it promotes the expression of phase II
antioxidant enzymes to protect against oxidative damage.
Among these phase II antioxidant enzymes, the role of heme-
oxygenase-1 (HO-1) must be highlighted.
HO-1 catalyzes the rate-limiting step of the degradation of
heme group generating carbon monoxide (CO); biliverdin,
which is rapidly converted to bilirubin by biliverdin reduc-
tase; and ferrous iron. Both HO-1 and its three by-products
have antioxidant and cytoprotective effects (2, 27), and HO-1
also has an anti-inflammatory effect as its activity is ac-
companied by the expression of IL-10 and IL-1bRa (34).
Interestingly, the HO-1/CO axis has been reported to control
mitochondrial biogenesis in a way that implies superoxide
dismutase 2 (SOD2) expression and mitochondrial H2O2
production, which leads to the induction of Nrf2 viaAkt/PKB
and binding to the NRF-1 promoter (47). As a result, this
transcriptional mechanism links the mitochondrial expansion
to the antioxidant and counterinflammatory defenses.
Microglia are considered the resident macrophages of the
CNS and are responsible for the brain’s innate immune sys-
tem. During aging, microglia lose their homeostastic func-
tional role and could contribute to neurodegeneration (45,
46). By improving glial mitochondrial function, the brain
could, in principle, better resolve inflammation and contrib-
ute to reduce pathology. Based on the participation of HO-1
in mitochondrial biogenesis (33, 34), in this study we have
focused on the participation of the glial a7 nAChR in the
generation of new mitochondria. Our results show that acti-
vation of a7 nAChR in glial cells increases mitochondrial
mass and improves cellular mitochondrial respiration, both
processes dependent on HO-1 and PGC-1a activity.
Results
The a7 nAChR agonist PNU282987 increased
mitochondrial mass in glial cells
Our group and others have previously described the anti-
inflammatory and antioxidant properties mediated by a7
nAChRs (12, 22). Due to the close relationship between those
processes and mitochondrial biogenesis (34, 43), we thought
of interest to study if a7 nAChR signaling could be increasing
the mitochondrial content. To address this question, we used
primary glial cultures treated with the specific a7 nAChR
agonist, PNU282987, at a concentration of 10lM during 48h;
thereafter, different methodological approaches were used to
evaluate if changes in mitochondrial mass were taking place.
Using the fluorescent stainMitoTracker-Green (Mtg), which is
characterized for being independent of mitochondrial poten-
tial, we measured the mitochondrial content by flow cytome-
try. With this protocol, we obtained that cells treated with
PNU282987 presented a higher mitochondrial content, com-
parable to the results obtained with the positive control re-
sveratrol (Fig. 1A). We also labeled glial cells with Mtg and
took images in a confocal microscope, observing higher
fluorescent levels in cells treated with PNU282987 (Fig. 1B).
To ensure the results above, the expression of mitochondrial
proteins, such as cytochrome c andmanganese SOD (MnSOD),
was also measured byWestern blot. As shown in Figure 1C and
Innovation
Increases in microglial mitochondrial mass and metab-
olism can be achieved via the a7 nicotinic acetylcholine
receptor (nAChR) by a mechanism that implicates nuclear
erythroid 2-related factor 2 (Nrf2) heme-oxygenase-1 (HO-
1) and peroxisome proliferator-activated receptor gamma
coactivator 1a (PGC-1a). By improving microglial mito-
chondrial function through activation of this new pathway,
the brain could, in principle, better resolve inflammation
and contribute to reduce pathology.
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D, PNU282987-treated glial cells increased by two- and
threefold the expression of cytochrome c and MnSOD, re-
spectively. Taken together, we can conclude that the treatment
of glial cells with the a7 nAChR agonist increased mitochon-
drial mass.
The increase in mitochondrial mass was not
associated with increased ROS production or
mitochondrial membrane potential alterations
The main source of oxidative stress within the cell is the mi-
tochondria and excessive ROS production can be deleterious to
the cells. Therefore, we analyzed if the increase inmitochondrial
content elicited byPNU282987was accompanied by an increase
in ROS production or alterations in mitochondrial membrane
potential. For that purpose, we labeled the cells with the fluo-
rescent dyes 2¢,7¢-dichlorofluorescein diacetate (H2DCFDA; to
measure ROS) and tetramethylrhodamine, ethyl ester, perchlo-
rate (TMRE; to assess changes in mitochondrial potential) and
analyzed them by flow cytometry.We obtained that the increase
in mitochondrial mass elicited by PNU282987 was not associ-
ated to changes in cellular redox status as we did not observe
changes in H2DCFDA fluorescence (Fig. 1E). Furthermore, no
mitochondrial membrane potential changes were detected using
the ratio TMRE/Mtg (Fig. 1F).
Glial cells exhibit a higher mitochondrial respiratory
efficiency after PNU282987 treatment
Changes in the cellular mitochondrial content are not al-
ways accompanied by alterations in respiratory parameters.
To assess if PNU282987 treatment had any effect on mito-
chondrial bioenergetics, we used the XF24 Extracellular Flux
Analyzer (Seahorse Bioscience, North Billerica, MA) to
FIG. 1. Treatment with PNU282987
10lM during 48h increases mito-
chondrial mass in primary glial cul-
ture. (A) Mitochondrial mass was
measured using Mtg fluorescent stain by
flow cytometry. PNU282987, as well as
the positive control resveratrol 10lM,
significantly increasedMtg fluorescence.
Values are expressed as mean–SEM
(n=5 different experiments). Analysis
was performed using one-way ANOVA
test. *p<0.05 compared to control. (B)
The copy number of mtDNA and nDNA
was assessed by PCR. PNU282987 in-
creased the ratio mtDNA/nDNA. Values
are expressed as mean–SEM of five to
six measures of two independent cul-
tures. (C) Representative images taken
by confocal microscopy of cells stained
with Mtg. (D, E) PNU282987 increased
the expression of the mitochondrial pro-
teins cytochrome c and MnSOD as
shown in the representative immunoblots
and quantification plots. Data correspond
to mean–SEM (n=9 different experi-
ments). Analysis was performed using
paired t-test. *p<0.05 versus control. (F)
PNU282987 treatment did not increase
ROS production or (G) modify mito-
chondrial membrane potential measured
by flow cytometry using H2DCFDA or
TMRE stains, respectively. Graphs rep-
resent mean–SEM (n= 3–4 different
experiments). Analysis was performed
using paired t-test. ANOVA, analysis of
variance; H2DCFDA, 2¢,7¢,-dichloro-
fluorescein diacetate; MnSOD, manga-
nese superoxide dismutase; mtDNA,
mitochondrial DNA; Mtg, MitoTracker-
Green; nDNA, nuclear DNA; PCR,
polymerase chain reaction; ROS, reac-
tive oxygen species; SEM, standard error
of the mean; TMRE, tetramethylrho-
damine, ethyl ester, perchlorate. To see
this illustration in color, the reader is re-
ferred to the web version of this article at
www.liebertpub.com/ars
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determine the oxygen consumption rate (OCR) in cultured
cells (Fig. 2A). OCR was measured in control conditions, after
the addition of oligomycin to determine the oxygen consump-
tion linked to ATP synthesis, and after the addition of the un-
coupling agent 2,4-dinitrophenol (DNP) to obtain the maximal
respiratory capacity. At the end of each measurement, rotenone
plus antimycinAwere added to completely blockmitochondrial
respiration and to determine the nonmitochondrial respiration.
This value was subtracted to all conditions.
Our results show that PNU282987 increased OCR levels
under basal conditions (Control 3.7 – 0.28 nmol/min$mg
protein; PNU282987: 4.65 – 0.29 nmol/min$mg protein;
Fig. 2B). Moreover, PNU282987 also increased the OCR
due to ATP turnover (Control: 1.14 – 0.18 nmol/min$mg
protein; PNU282987: 1.65 – 0.15 nmol/min$mg protein;
Fig. 2C), whereas it had no effect on the proton leak
(Fig. 2D). The a7 nAChR agonist also improved themaximal
respiratory capacity of glial cells (Control: 3.81 – 0.24 nmol/
min$mg protein; PNU282987: 4.69 – 0.26 nmol/min$mg
protein; Fig. 2E). Taken together, these results indicate that
the increase in mitochondrial mass elicited by PNU282987
treatment is accompanied by an increase in mitochondrial
oxygen consumption and ATP synthesis.
Changes observed in mitochondrial mass were
a7 nAChR specific and dependent on Nrf2/HO-1
It has been previously described how signaling mediated
by a7 nAChR leads to an induction in HO-1 enzyme via Nrf2
transcription factor (22, 31). Since HO-1 has been reported to
participate in mitochondrial biogenesis (33, 38), we decided
to evaluate the implication of Nrf2/HO-1 in the effects eli-
cited by PNU282987.
First of all, we performed glial cultures from wild-type
(WT) and Nrf2-/- mice and observed that the increase in mi-
tochondrial population elicited by PNU282987 was lost when
Nrf2 was absent (Fig. 3A). To study the implication of HO-1,
we first confirmed that treatment with the a7 nAChR agonist
produced an induction of the enzyme; indeed, PNU282987
almost doubled the basal expression of HO-1 (Fig. 3B). Then,
by inhibiting HO-1 with 3lM tin protoporphyrin-IX dichlor-
ide (SnPP), the increase in mitochondrial mass induced by the
a7 nAChR agonist was lost (Fig. 3B). Furthermore, we used
100 nM a-bungarotoxin (a-Bgtx) as an a7 nAChR blocker to
determine that the effects observed with PNU282987 were re-
ceptor specific. Glial cultures were treated with PNU282987, in
the absence or presence of the HO-1 and a7 nAChR inhibitors,
and thereafter, mitochondrial mass and respiratory parameters
were assessed. When cells were treated during 48 h with
PNU282987 (10lM) in the presence of a-Bgtx, changes ob-
served in mitochondrial mass (Fig. 3C) and respiratory param-
eters (basal and maximal respiration, and ATP turnover) were
abolished (Fig. 3D, E), indicating that the effects elicited by
PNU282987 were specific of a7 nAChR activation. Moreover,
the increase in mitochondrial mass (Fig. 3C) and mitochondrial
respiration (basal and maximal respiration and ATP turnover)
observed with the a7 nAChR agonist was lost when HO-1 was
inhibited (Fig. 3D, E). Changes in proton leakwere not observed
among the different treatments.
These results provide a clear indication that induction of
HO-1 via Nrf2 is necessary for mitochondrial biogenesis
within the signaling pathway activated by a7 nAChR.
The increase in mitochondrial mass elicited
by PNU282987 was dependent on PGC-1a activity
PGC-1a has been widely described as the master regulator of
mitochondrial biogenesis but little is known about its relation-
ship with a7 nAChR signaling. In this study, we demonstrate
that activation of a7 nAChR produces an increase in the ex-
pression of PGC-1a measured by Western blot (Fig. 4A). We
also observed activation of pAMPK and pCREB; two proteins
associated with the activation of PGC-1a (Fig. 4B, C).
Moreover, mouse embryonic fibroblast (MEF) cells were
transfected with the PGC-1a promoter linked to a luciferase
reporter gene and they showed increased luciferase activ-
ity after Nrf2 transfection or sulforaphane (Sfn) treatment
FIG. 2. PNU282987 treatment increased mitochondrial
respiratory parameters in glial cultures. (A) Representative
plot of the OCR measured in control cells and cells treated
with PNU282987 10lM during 48h. The sequential additions
are indicated by arrows: 5lg/ml oligomycin (O), 500lM DNP
(D), and 1lM rotenone +1lM antimycin A (R+AA). Plots of
OCR quantification corrected using total mg of protein. (B)
basal: OCR under basal situation, (C) ATP turnover: basal
minus oligomycin, (D) proton leak: OCR after the addition of
oligomycin, (E) maximal respiration: OCR after the addition
of DNP. Nonmitochondrial respiration (rotenone plus anti-
mycin A) was subtracted for each condition. Graphs represent
mean–SEM of six independent experiments. Analysis was
performed using paired t-test. *p<0.05 versus control situa-
tion. ATP, adenosine triphosphate; DNP, 2,4,-dinitrophenol;
OCR, oxygen consumption rate.
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FIG. 3. The effect of PNU282987 on mitochondrial biogenesis depends on the a7 nAChR/Nrf2/HO-1 axis. (A)
Mitochondrial mass was assessed as Mtg fluorescence by FACS in WT and Nrf2-/- mice. PNU282987 increased the number
of mitochondria in WT cultures but not in Nrf2-/-. Values represent mean – SEM of eight to nine independent experiments.
Analysis was performed using two-way ANOVA. *p< 0.05 versus control situation. (B) The treatment with PNU282987
increased the expression of HO-1 measured by Western blot. Data correspond to mean –SEM of three independent
experiments. Analysis was performed using paired t-test. *p< 0.05 versus control situation. (C) The effects of PNU282987
on mitochondrial mass, measured as Mtg fluorescence by flow cytometry in the presence of 100 nM of a-Bgtx and 3 lM of
SnPP, were abolished. Values represented are mean – SEM (n = 4 independent experiments). Analysis was performed using
one-way ANOVA test. ***p < 0.001 versus control, ##p < 0.01 versus PNU282987. (D) Representative plot of the OCR
measured in control cells and in cells exposed to PNU282987 10lM during 48 h, in the presence or absence of 100 nM a-
Bgtx or 3 lM SnPP. The sequential additions are indicated by arrows: 5 lg/ml oligomycin (O), 500lM DNP (D), and 1 lM
rotenone +1lM antimycin A (R+AA). Plots of OCR quantification corrected using total mg of protein: (E) basal conditions,
(F) ATP turnover: basal minus oligomycin, (G) proton leak: OCR after the addition of oligomycin, (H) maximal respiration:
OCR after the addition of DNP. Nonmitochondrial respiration (rotenone plus antimycin A) was subtracted for each
condition. Graphs represent mean – SEM of four independent experiments. Analysis was performed using one-way AN-
OVA. *p < 0.05 versus control, #p < 0.05 versus PNU282987, ##p < 0.01 versus PNU282987. a7 nAChr, alpha7 nicotinic
acetylcholine receptor; a-Bgtx, alpha-bungarotoxin; HO-1, heme-oxygenase-1; Nrf2, nuclear erythroid 2-related factor 2;
SnPP, tin protoporphyrin-IX dichloride; WT, wild type.
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(potent inductor of Nrf2). These results provide evidence on
the possible regulation of the expression of PGC-1a via Nrf2
transcription factor.
To assess the implication of PGC-1a in mitochondrial bio-
genesis activated by a7 nAChR, we used adeno-associated viral
infection to silence the expression of PGC-1a and then studied
the effect of PNU282987 treatment. Cells were infected for 8 h
with the adeno-associatedvectors expressing (i) scrambled small
hairpin RNA (shRNA; shControl) and (ii) shRNA targeting
PGC-1a (shPGC-1a), followed by overnight cell recovery. As
shown by Western blot, PGC-1a was silenced in glial cells
treated with shPG-1a and not in those treated with scrambled
shRNA (Fig. 4E). Afterward, PNU282987 was added during
48 h and mitochondrial mass was assessed as Mtg fluorescence
by flow cytometry. As it can be observed in Figure 4F, PGC-1a
silencing prevented the changes in mitochondrial mass elicited
by PNU282987, highlighting the implication of PGC-1a in the
effect that PNU282987 had on this process.
Repeated intraperitoneal injection of PNU282987
increased mitochondrial content specifically
in microglia only when HO-1 and PGC-1a were present
To further confirm our results, we decided to assess if the
increase inmitochondrial massmediated via a7 nAChR could be
reproduced in vivo. For that purpose, we performed repeated
intraperitoneal (i.p.) injections (twice per day) of 10mg/kg of
PNU282987 during 2 days (Fig. 5A). Body weight was moni-
tored throughout the experiment, but no changes were observed
(data not shown). Forty-eight hours after the first injection, ani-
mals were sacrificed; the microglial population was isolated by
Percoll gradient and cells were stained with CD45-FITC,
CD11b-PE, and GLAST-APC to confirm the purity of the mi-
croglial enrichment protocol.As shown in Figure 5B, the isolated
population was positive for CD11b (microglial marker), ex-
pressed low levels of CD45 (macrophage marker), and was
negative for GLAST (astrocytic marker), indicating that the
population isolatedwas indeedmicroglia (purity: 82.1%–3.4%).
Once the purity of the population was established, cells
were stained with CD11b and Mtg to evaluate changes in
mitochondrial content in CD11b+ cells after PNU282987
injection. As represented in Figure 5C and D, PNU282987
treatment elicited a significant increase in mitochondrial
content in the microglial population of WT animals (Saline:
1.0 – 0.09 vs. PNU282987: 1.3 – 0.08).
To establish conclusively the involvement of HO-1 in the
effects of a7 nAChR stimulation on mitochondrial biogene-
sis, we performed the same experiment using LysMcre-
Hmox1D/D animals, in which HO-1 expression is absent
specifically in myeloid cells. The results were normalized
FIG. 4. PGC-1a participates in the effect of PNU282987 on mitochondrial mass. (A) PNU282987 increased the
expression of PGC-1a measured by Western blot. Data correspond to mean – SEM of four independent experiments.
Analysis was performed using paired t-test. *p < 0.05 versus control situation. (B) PNU282987 increased the phosphory-
lation of AMPK protein and (C) CREB transcription factor. Data correspond to mean and SEM (n = 4–6 independent
experiments). Analysis was performed using paired t-test. *p< 0.05 versus control. (D) MEFs were transfected with the
PGC-1a promoter linked to luciferase reporter gene and they were either cotransfected with Nrf2 plasmid of treated with
10 lM Sfn. Both Nrf2 and Sfn produced an increase in luciferase activity. Data represent mean and SEM of three
independent experiments performed in duplicate. **p< 0.01 versus control condition. (E) Efficacy of silencing PGC-1a was
assessed by Western blot in control glial cells silenced using adeno-associated viral vectors. (F) Quantification plot of Mtg
fluorescence after treatment with PNU282987 in cells infected with adeno-associated virus with scrambled RNA
(shControl) or shPGC-1a. Data are mean – SEM (n = 5 independent experiments). Analysis was performed using two-way
ANOVA test. **p < 0.01 versus control. MEFs, mouse embryonic fibroblasts; PGC-1a, peroxisome proliferator-activated
receptor gamma coactivator 1a; Sfn, sulforaphane; sh, small hairpin.
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FIG. 5. Repeated i.p. injection of PNU282987 increases mitochondrial mass in vivo specifically in microglial pop-
ulation: HO-1 and PGC-1a dependency. (A) Experimental protocol. PNU282987 was administered i.p. 10mg/kg twice
per day during 2 days. (B) Microglial population purity. Microglia were isolated using Percoll gradient, and purity was
measured by flow cytometry using the markers CD11b, CD45, and GLAST. (C, D) PNU282987 treatment increased
mitochondrial content in microglial population in WT animals. Mitochondrial content was assessed in CD11b-positive cells
using Mtg fluorescent staining. (C) Representative flow cytometry plot and (D) quantification plot. Data correspond to mean
and SEM (n = 8 animals treated with saline and n = 6 animals treated with PNU282987). *p < 0.05 versus saline. (E, F)
Animals that did not express HO-1 in myeloid lineage (LysMcre-Hmox1D/D) showed decreased number of mitochondria in
microglia compared to their controls and PNU282987 did not produce any increase. Representative flow cytometry plot (E)
and quantification plot (F). Data correspond to mean and SEM (n = 6 animals/group). (G, H) Animals PGC-1a-/- also
showed decreased levels of microglial mitochondria and no changes were observed after the treatment with PNU282987.
(G) Representative flow cytometry plot and (H) quantification plot. Data correspond to mean and SEM (n = 4 animals/
group). In all cases, analysis was performed using paired t-test. i.p., intraperitoneal. To see this illustration in color, the
reader is referred to the web version of this article at www.liebertpub.com/ars
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against their age control littermates, named as WT. Noteworthy
was the finding that LysMcre-Hmox1D/D mice injected with sa-
line presented lower mitochondrial content in comparison with
their age control littermates (WT Saline: 1.0–0.08 vs. LysMcre-
Hmox1D/DSaline: 0.78– 0.057;Fig. 5D,F).Moreover,LysMcre-
Hmox1D/D animals injected with PNU282987 did not show an
increase in mitochondrial content (LysMcre-Hmox1D/D Saline:
0.78–0.056 vs. PNU282987: 0.71–0.16; Fig. 5E, F), corrobo-
rating the previous results obtained in vitro (Fig. 3).
Wealso aimed to further demonstrate the implication of PGC-
1a in the effect of PNU282987 onmitochondrial biogenesis; for
this issue we used PGC-1a-/- mice. The absence of PGC-1a
produced similar effects to those found in LysMcre-Hmox1D/D
mice. When we analyzed the mitochondrial content in the mi-
croglial population, we also observed a decrease in mitochon-
drial mass in these animals when normalized against PGC-1a+/+
(named as WT; WT Saline: 1.0–0.04 vs. PGC-1a-/- Saline:
0.83–0.063; Fig. 5D, H). Moreover, when PGC-1a-/- animals
were injected with PNU282987, no changes were observed in
mitochondrial content (PGC-1a-/-Saline: 0.83–0.063 vs.PGC-
1a-/- PNU282987: 0.89–0.13; Fig. 5G, H). These observations
are in concordance with the results obtained in vitro (Fig. 4).
Taken together, these results highlight the implication of
a7 nAChR in promoting mitochondrial biogenesis not only
in vitro but also in vivo. Moreover, we provide clear evidence
that HO-1 and PGC-1a are necessary to induce the increase in
the number of mitochondria elicited by a7 nAChR activation.
Discussion
In this study we show as far as we know, for the first time,
that a7 nAChR activation increases the mitochondrial con-
tent and respiratory capacity in microglia by a mechanism
that implicates Nrf2, HO-1, and PGC-1a.
Mitochondria are crucial organelles for cellular homeosta-
sis, which govern pivotal functions such as ATP production,
calcium homeostasis, and apoptosis; therefore, it is known that
processes which alter mitochondrial activity can lead to dis-
ease. During neurodegeneration, besides mitochondrial dys-
function, a decrease in cholinergic markers such as nAChRs
has been recognized (35). Among nAChRs, the a7 subtype is
emerging as an interesting target for neuroprotection as it is
implicated in a variety of processes. In the CNS, a7 nAChRs
are expressed not only in neuronal cells, where they participate
in neurotransmission and neurite outgrowth, but also in non-
neuronal cells where they participate in several functions such
as the control of inflammation (12).
In this study, we provide data for a new effect of the a7
nAChR, such as mitochondrial energetics. Indeed, we have
described that a7 nAChR activation (using PNU282987 as
agonist) activates glial mitochondrial biogenesis in vitro and
in vivo, as evidenced by the following results: (i) treatment of
glial cells with PNU282987 increased cellular mitochondrial
mass (Fig. 1A–D); (ii) PNU282987 improved mitochondrial
respiration (increasing basal oxygen consumption,ATP-linked
respiration, and maximal respiration; Fig. 2); and (iii) i.p. ad-
ministration of PNU282987 (10mg/kg) increased mitochon-
drial mass in the microglial population in vivo (Fig. 5C, D).
As a decrease in the number and function of mitochondria
seems to play a pivotal role in the development of a wide
variety of pathologies such as Alzheimer’s disease (AD) or
Parkinson’s disease (PD), these results position a7 nAChRs
as target for neuroprotection. For instance, AD brains are also
characterized by a decreased expression of mitochondrial
complexes, decreased blood flow, and metabolic failure (16,
21, 37). Moreover, amyloid-beta (Ab) and tau, both proteins
associated to AD, have been reported to inhibit the activity of
mitochondrial complexes of the electron transport chain,
which derives in decreased synthesis of ATP (39).
Similarly, there are also bioenergetic defects associated to
PD. For instance, mutations in parkin, which is a leading
cause of PD development, alter mitochondrial biogenesis
causing a loss in dopaminergic neurons (44). Moreover, de-
creases of ATP levels have been related to the widely re-
ported decreased activity in complex I (14, 32, 42).
Furthermore, the mitochondrial dysfunction associated to
both diseases and other NDDs produces increased ROS levels
which, in turn, trigger mitochondrial DNA (mtDNA) muta-
tions, inhibit mitochondrial proliferation, and increase apo-
ptosis, which finally lead to neurodegeneration (4a).
To understand the pathway by which a7 nAChR activates
mitochondrial biogenesis, we have focused on the Nrf2/HO-1
axis. Our group has previously described that the neuropro-
tective properties mediated by a7 nAChR depend on the acti-
vation of the Jak2/PI3K/Akt cascade, which finally leads to an
overexpression of HO-1 via Nrf2 transcription factor (9, 31).
In this study, we have shown that Nrf2 and HO-1 are
necessary for the effects of PNU282987 on mitochondrial
mass and function as indicated by the following evidences: (i)
PNU282987 did not increase mitochondrial mass in Nrf2-/-
animals (Fig. 3A), (ii) the specific inhibitor of HO-1 (SnPP)
prevented the increase in mitochondrial mass produced by
PNU282987 (Fig. 3C), (iii) a7 nAChR did not produce an
increase in mitochondrial respiratory parameters when HO-1
was inhibited (Fig. 3D), and (iv) LysMcre-Hmox1D/D animals
injected with PNU282987 did not show an increase in mi-
croglial mitochondrial mass (Fig. 5E, F).
Several authors have previously described that HO-1 could
be involved in mitochondrial biogenesis, although the
mechanism has not been completely elucidated. This idea
was raised by Suliman et al. who reported in 2007 that CO, a
by-product of HO-1, increased cardiac mitochondrial bio-
genesis (47). These results have been corroborated also in
hepatoma cells, where mitochondrial biogenesis was acti-
vated using a CO-releasing molecule and cobalt protopor-
phyrin (a HO-1 inducing agent) (15).
These authors demonstrated that this process was abol-
ished when using a CO scavenger, indicating the implication
of this by-product. Piantadosi et al. proposed that CO pro-
duced by HO-1 would cause the release of H2O2 from mi-
tochondria, which could be activating the Nrf2 transcription
factor that binds to the antioxidant response elements (ARE)
activating the expression of a wide variety of genes, among
them NRF-1, and thus activating mitochondrial biogenesis
(33). Although the exact mechanism should be further in-
vestigated, our results corroborate the implication of Nrf2/
HO-1 in the generation of new mitochondria.
As stated in the Introduction section, PGC-1a is considered
the master regulator of mitochondrial biogenesis. In this
study, we show that activation of a7 nAChR increases the
expression of this transcriptional factor (Fig. 4A), which
participates in the changes in mitochondrial mass elicited by
PNU282987 (Fig. 4F). There are evidences in the literature
that would link the expression of PGC-1a to Nrf2. Indeed,
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both transcription factors have overlapping functions in
regulating the antioxidant system, having been described to
increase the expression of SODs or glutathione peroxidase 1
(3), among other antioxidant enzymes. These notions raise
the possibility that the expression of one gene could be reg-
ulated by the expression of the other.
In this line, PGC-1a has been described to increase the ex-
pression of Nrf2 in a model of metabolic imbalance (1), al-
though the direct interaction between them has not been
demonstrated. Nevertheless, no changes in Nrf2 mRNA levels
were observedwhen comparingWT and PGC-1a-/-MEF cells
(26). On the contrary, the PGC-1a promoter has two ARE core
sequences (3, 43) even though they have not been demon-
strated to be active. To assess this last regulation,weusedPGC-
1a promoter linked to luciferase reporter gene andwe observed
that Nrf2 increased the luciferase activity, indicating that Nrf2
could be controlling the expression of PGC-1a. In addition,
pAMPK and pCREB could also be implicated in the activation
of PGC-1a since these proteins were also upregulated in cells
treated with the a7 nAChR agonist (Fig. 4B, C).
Taking into account that a decrease in PGC-1a or alterations
in its signaling have been described in NDDs (4a) and PGC-1a
knockout mice show neuropathology at earlier stages (17),
these results are interesting from a pharmacological point of
view. For that reason, compounds that could restore energy
production and antioxidant capacity would be useful for the
treatment of these pathologies and this is why PGC-1a is
emerging as a new therapeutic target for neurodegenerative
disorders (4a). Our results describe that the changes in mito-
chondrial mass elicited by a7 nAChR depend on the activation
of PGC-1a as we did not observe mitochondrial biogenesis
when we silenced PGC-1a in glial cultures (Fig. 4E) or when
we used PGC-1a knockoutmice (Fig. 5E, F). In conclusion, we
describe a new pathway for increasing PGC-1a, which in turn
increases mitochondrial content.
Interestingly, we have observed that the increase in mito-
chondrial number and activity derived from PNU282987
treatment was not accompanied by alteration in the mito-
chondrial membrane potential or an increase in the produc-
tion of ROS (Fig. 1E, F). These results could be explained by
the fact that the mechanism by which PNU282987 increased
mitochondrial mass implicates PGC-1a and HO-1. PGC-1a
has been reported to not only trigger the generation of new
mitochondria but to also improve the antioxidant capacity
and suppress ROS (43). Regarding HO-1, it is considered that
both the enzyme itself and also its by-products have antiox-
idant properties, which could contribute to the maintenance
of oxidative stress levels.
Although the aerobic respiration and generation of ATP
have been considered the principal function of mitochondria,
recent studies indicate the implication of mitochondria in
controlling the inflammatory response (34, 48). Since a7
nAChRs have anti-inflammatory properties in macrophages
(19, 49) and microglia (11, 30), we hypothesize that a po-
tential link between the anti-inflammatory response and the
increase in the cellular energetic capacity may coexist, al-
though further studies need to be done to confirm this.
In conclusion, with this study we have progressed in the
knowledge of a7 nAChR signaling. We describe for the first
time how a7 nAChR activation, specifically in glia, increases
not only mitochondrial mass but also mitochondrial function,
showing a new mechanism that could complement the pro-
tective and anti-inflammatory properties of a7 nAChR sig-
naling. We also provide mechanistic evidences showing the
implication of HO-1 and PGC-1a, both controlled under Nrf2.
It should be noted that, apart from mitochondrial biogen-
esis, there are other processes necessary for the quality con-
trol of these organelles, such as mitochondrial fusion,
mitochondrial mobility, or mitophagy. Whether a7 nAChR
has the ability to control these processes remains unexplored
and should be studied to better understand the implication of
a7 nAChR in the mitochondrial network. Nevertheless, so far
we can firmly conclude that microglial a7 nAChR improves
mitochondrial functioning and this effect can be comple-
mentary to its anti-neuroinflammatory and neuroprotective
properties for the treatment of NDDs.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium: nutrient mixture
F-12 (DMEM-F12) and fetal bovine serum (FBS)were obtained
from Invitrogen (Madrid, Spain). Penicillin/Streptomycin
purchased from Sigma (Madrid, Spain). TMRE, H2DCFDA,
Mtg-FM, and Hoechst were purchased from Molecular
Probes (Invitrogen). PNU282987 and a-Bgtx were purchased
from Tocris Scientific/Biogen (Madrid, Spain), SnPP from
Frontier Scientific Europe (Lancashire, United Kingdom),
CD45-FITC, CD11b-PE, and GLAST-APC were purchased
from Miltenyi Biotec (Madrid, Spain).
Animals
All animal assays were carried out following the Guide for
the Care and Use of Laboratory Animals and were previously
approved by the Institutional Ethics Committee of Uni-
versidad Auto´noma de Madrid, Spain, according to the Eu-
ropean Guidelines for the use and care of animals for research
in accordance with the European Union Directive of Sep-
tember 22, 2010 (2010/63/UE), and with the Spanish Royal
Decree of February 1, 2013 (53/2013). All efforts were made
to minimize the number of animals used and their suffering.
Mixed glial culture
Glial culture was performed using neonatal Sprague-
Dawley rats (2–4 days old) as described before (29). Briefly,
brain cortex was removed, mechanically homogenized, and
passed through a 70-lmnylon filter. Cells were centrifuged at
1000 rpm for 5min and plated at a density of 300,000 cells/ml
in DMEM/F12 supplemented with 20% FBS. After 5 days
in vitro (DIV), the mediumwas replaced by DMEM/F12 10%
FBS. The medium was changed twice a week and experi-
ments were performed after 7/10 DIV. The same protocol
was used for mice glial cultures (WT and Nrf2-/-) In all
treatments, PNU282987was used at a concentration of 10 lM
during 48 h.
Flow cytometry
Samples were analyzed using Cytomics FC500 (Beckman
Coulter, Madrid, Spain). Briefly, after the treatments, cells
were collected and after centrifugation they were resuspended
in 100ll 1· binding buffer (BD Biosciences, Madrid, Spain)
containing the appropriate concentration of fluorescent dye
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(MitoTracker Green-FM 100 nM, H2DCFDA 1lM, TMRE
100 nM, CD45-FITC, CD11b-PE, and GLAST-APC 1:100).
After a 15-min incubation in the dark, 200ll of phosphate
buffered saline (PBS) 1·was added. Cells were then subjected
to FACS analysis with a total of 10,000 events per assay.
Mitochondrial copy number
Once the experiment was finished, cells were washed with
PBS and DNA was isolated as follows. Cells were lysed in
500ll of buffer containing 1M Tris-HCl (pH 8), 5M NaCl,
0.5M EDTA, 10% sodium dodecyl sulfate (SDS), and 0.5mg/
ml proteinase K. After 2 h at 55C, 500ll of phenol/chloro-
form/isoamyl alcoholwas added andmixed byvortex. Samples
were centrifuged at 13,000 rpm for 10min and the aqueous
phase was transferred to a solution containing 0.7 (v/v) iso-
propanol and 0.3 sodium acetate 2 M at 50%. Samples were
centrifuged 15min at 13,000 rpm, and pellets were washed
with 70% ethanol. After 5min at 13,000 rpm centrifugation,
pellets were dried and resuspended in water. DNA was am-
plified by quantitative polymerase chain reaction using the
following primers: COII (subunit II cytochrome oxidase):
F-CATTATTCCTAGAACCAGGCAGAC and R-GAATTA
ATTCTAGGACGATGGGC; b-actin: F-CACCTTCCAGCA
GATGTGGA and R-AGCATTTGCGGTGGACGATGG.
The ratio COII/b-actin represents mtDNA/nuclear DNA (nDNA).
Immunofluorescence
Once the experiment was finished, cells were washed three
times with PBS (NaCl 9 g/L, 10mM NaH2PO4, 10mM
K2HPO4) and stained with the mitochondrial fluorescent stain
MitoTracker Green FM (100 nM) for 20min. Then, cells
were washed three times with PBS and the nuclear marker
Hoechst (1 lg/ml) was added in the second wash. Finally,
images were taken with a confocal microscope (TCS SPE;
Leica, Wetzlar, Germany) with a magnification of 63 · .
Western blot
After treatment, cells were lysed in ice-cold lysis buffer (1%
Nonidet P-40, 10% glycerol, 137mM NaCl, 20mM Tris–HCl,
pH 7.5, 1lg/ml leupeptin, 1mM phenylmethylsulfonyl fluo-
ride, 20mM NaF, 1mM sodium pyrophosphate, and 1mM
Na3VO4) supplemented with one tablet of protease inhibitor
cocktail (CompleteMini; Roche,Mannhein, Germany). Thirty
micrograms of protein lysates was resolved by polyacrylamide
gel electrophoresis-SDS and transferred to immobilon-P
membranes (Millipore Iberica, SA, Madrid, Spain). Mem-
branes were incubated with anti-AMPKa [pT172] (1:1000;
Invitrogen), anti-AMPKa (1:500; Invitrogen), anti-p-CREB
[Ser133] (1:1000; Cell Signaling), anti-CREB (1:1000; Cell
Signaling), anti-HO-1 (1:1000; Santa Cruz), anti-PGC-1a
(1:1000; Cayman Chemical), anti-MnSOD (1:1000; Stress-
gen), anti-cytochrome c (1:1000; BD PharMingen), anti-p-85-
PI3K (1:50,000; Merck Millipore), anti-tubulin (1:10,000;
Calbiochem), and anti-b-actin (1:100,000; Sigma).
Measurement of OCR in cultured cells
Oxygen consumption was measured using the XF24 Ex-
tracellular Flux Analyzer (Seahorse Bioscience). To obtain a
homogeneous monolayer of cells, 150,000 cells per well were
plated in XF24 cell culture microplates (Seahorse Bioscience)
7–10 days before the experiment.
To study the effect of PNU282987 on cell respiration, glial
cells were exposed to 10lM PNU282987 for 48 h and then
incubated in unbuffered DMEM supplemented with 25mM
glucose, 1mM pyruvate, and 2mM glutamine at 37C in a
CO2-free incubator for 1 h for equilibration before the ex-
periment, period in which PNU282987 treatment was main-
tained in the unbuffered DMEM. A calibration cartridge
(Seahorse Bioscience) was equilibrated overnight and then
loaded with unbuffered DMEM (port A), 5 lg/ml oligomycin
(port B), 500lMDNP (port C), and 1lM rotenone plus 1lM
antimycin A (port D), all obtained from Sigma-Aldrich. This
allowed the determination of basal respiration, the amount of
oxygen consumption linked to ATP production, the proton
leak, the maximal respiration capacity, the reserve capacity,
and the nonmitochondrial oxygen consumption. In all ex-
periments, the protein concentration in each well was deter-
mined at the end of the measurements, using the Pierce BCA
protein assay kit (Thermo Scientific) after cell lysis in RIPA
buffer (Sigma-Aldrich) supplemented with protease inhibitor
cocktail (Complete Mini; Roche), and was used to calibrate
the oxygen consumption data.
Luciferase assay
For this assay, we used immortalized MEF cells derived
from WT C57BL/6 mice. They were transfected using Li-
pofectamine 2000 with 100 ng of a plasmid containing 2 kb
of PGC-1a promoter linked to luciferase reporter gene (4). In
addition, cells were transfected with 200 ng of either empty
vector (pcDNA3.1) as control or with an expression factor of
V5-tagged Nrf2 [pcDNA3.1-Nrf2-V5, kind gift of John
Huyes (20)]. Twenty-four hours later, cells were treated with
Sfn 10 lM or vehicle for 48 h. Forty-eight hours post-
transfection, luciferase activity was determined with the
Dual-Luciferase Reporter Assay System (Promega).
Adenoviral vectors and infections
Silencing Ad-shPGC-1a was constructed using the pSi-
lencerTM Adeno 1.0 Cytomegalo-virus Promoter System
from Ambion (Carlsbad, CA), as previously described (26).
Primary glial cultures were infected during 8 h with adeno-
viral vectors. After infection, the medium was changed for
cell recovery overnight, and then cells were treated for 48 h
with PNU282987 10 lM.
Animal treatments
In vivo experiments were performed using C57BL/6 mice
as WT at the age of 8–10 weeks. PNU282987 was adminis-
tered at a concentration of 10mg/kg by i.p. injection twice per
day during 2 days.
LysMCreHmox1D/D were generated in the Universidad
Auto´noma de Madrid from C57BL/6 Hmox1LoxP x LysMCre
mice (29). Hmox1LoxP mice were generated by the labora-
tory of Dr. Masayuki Yamamoto (Tohoku University
Graduate School of Medicine) (18). They were obtained
through RIKEN BioResource Center (B6J.129P2 Hmox1).
C57BL/6 LysMCre mice were generated by the laboratory
of Dr. Forster (5) and obtained through the Jackson La-
boratory [B6.129P2-Lyz2tm1(cre)Ifo/J Stock No. 004781].
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Mice were used at 8–10 weeks of age and littermates were
used as controls.
PGC-1a+/+ and PGC-1a-/- mice were originally provided
by Dr. Bruce Spiegelman (Dana-Farber Cancer Institute,
Harvard Medical School) and following embryo transfer, a
colony was established at the Instituto de Investigaciones
Biome´dicas (Madrid, Spain). Mice were used at 8–10 weeks
of age and littermates as controls.
Microglial isolation
Microglia were isolated from whole-brain homogenates
using Percoll gradient as previously described (23, 24).
Briefly, animals were killed and brains were homogenized by
passing through a 70-lM cell strainer using PBS 1 · (pH 7.4).
Homogenates were centrifuged at 600· g during 6min at
10C. Thereafter, brains were resuspended in isotonic Percoll
of 70% and a discontinuous Percoll gradient was layered
(70%, 50%, 35%, and 0%). The gradient was centrifuged at
2000 · g during 20min at 10C. Microglia were collected
from the interface between 50% and 70% layers and cells
were washed with PBS and ready for flow cytometry analysis.
Statistical analysis
Results are expressed as mean – standard error of the
mean. Statistical analysis was performed using GraphPad
Prism 5.0 program. Every independent experiment was nor-
malized with respect to control situation and the remaining
variables were referred to that value. Analysis was performed
using the following tests: paired t-test, one-way analysis of
variance (ANOVA) followed by Newman–Keuls post-hoc
test or two-way ANOVA followed by Bonferroni post-hoc
test. Statistical significance was considered when p £ 0.05.
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Abbreviations Used
a7 nAChR¼ alpha7 nicotinic acetylcholine receptor
a-Bgtx¼ alpha-bungarotoxin
AD¼Alzheimer’s disease
ANOVA¼ analysis of variance
ARE¼ antioxidant response elements
ATP¼ adenosine triphosphate
CNS¼ central nervous system
CO¼ carbon monoxide
DIV¼ days in vitro
DNP¼ 2,4,-dinitrophenol
FBS¼ fetal bovine serum
H2DCFDA¼ 2¢,7¢-dichlorofluorescein diacetate
HO-1¼ heme-oxygenase-1
i.p.¼ intraperitoneal
MnSOD¼manganese superoxide dismutase
mtDNA¼mitochondrial DNA
Mtg¼MitoTracker-Green
NDDs¼ neurodegenerative diseases
Nrf2¼ nuclear erythroid 2-related factor 2
NRFs¼ nuclear respiratory factors
OCR¼ oxygen consumption rate
PBS¼ phosphate buffered saline
PD¼ Parkinson’s disease
PGC-1a¼ peroxisome proliferator-activated
receptor gamma coactivator 1a
PPARs¼ peroxisome proliferator-activated
receptors
ROS¼ reactive oxygen species
SDS¼ sodium dodecyl sulfate
SEM¼ standard error of the mean
Sfn¼ sulforaphane
sh¼ small hairpin
SnPP¼ tin protoporphyrin-IX dichloride
SOD¼ superoxide dismutase
TMRE¼ tetramethylrhodamine, ethyl ester,
perchlorate
WT¼wild type
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